Ind-Swift Laboratories Share Price

    NSE
    105.23
    -11.50 (9.95%)
    INDSWFTLAB • 10 Jul, 2025 | 03:29 PM
    BUY

    1Y Annualised Return

    -21.50%

    3Y Annualised Return

    20.71%

    5Y Annualised Return

    25.22%

    The current prices are delayed, login or Open Demat Account for live prices.

    Ind-Swift Laboratories Stock Performance

    1W Return-7.37
    1Y Return-21.50
    Today's Low105
    Prev. Close116.73
    Mkt Cap (Cr.)640.38
    1M Return-4.20
    3Y Return74.61
    52-Week High186
    Open116.73
    PE Ratio7.14
    6M Return2.66
    Today's High119.37
    52-Week Low68.72
    Face Value10

    Ind-Swift Laboratories Company background

    Founded in: 1995
    Managing director: N R Munjal
    IndSwift Laboratories Limited is a part of the IndSwift Group and is based at Chandigarh, India. The Company is one of the leading manufacturers of APIs catering to global and domestic formulators. Based in Chandigarh, India, the Company operated two advanced manufacturing facilities in Derabassi and Jammu, adhering to international standards. IndSwift Laboratories Ltd. is recognised globally as a leader in the Macrolide Antibiotic sector, and its products are wellregarded by major pharmaceutical formulators worldwide.IndSwift Laboratories Limited was incorporated on January 4, 1995 as a joint venture between IndSwift Ltd and Punjab State Industrial Development Corporation. Later, IndSwift purchased Punjab State Industrial Development Corporation equity to emerge as a single largest shareholder in the company. The company commenced their production in the year 1997. Over a short period, the company has emerged as a respectable and dependable supplier of BulkActives in more than 40 countries.In the year 1997, the company went public and concentrated on the manufacture of Active Pharmaceutical Ingredients (API). In the year 199899, they launched two molecules, Clarithromycin and Roxithromycin. Their inhouse RD developed Clarithromycin Granules for the first time in India.In the year 2000, the company developed a new drug namely, Astrovastatin. In addition, they entered into an agreement with eight international pharmaceutical companies to source their requirements for Clarithromycin Fexofenadine Roxithromycin and Candesartan from the company.During the year 200304, the company increased the production capacity of bulk drugs/ intermediates from 81.18 TPA to 120 TPA. In addition, they commissioned the granulation facility as per CGMP standards. They launched four new products namely, Acamprosate (alcohol abstinence), Ezetimibe (antihyperlipidemic), Anastrazole (oncology) and Nitazoxanide (antidiarroheal). In January 2, 2004, the company incorporated a wholly owned subsidiary, namely IndSwift Laboratories Inc in USA to strengthen the companys presence in contract research and manufacturing services. In June 2004, the subsidiary company commenced their operations.During the year 200405, the company expanded the production capacity of bulk drugs/ intermediates from 120 TPA to 150 TPA. They commissioned waste heat recovery unit to reduce energy costs. They opened and office in China to facilitate the import of raw materials. The company introduced five new products in the market. During the year 200506, the company completed and commissioned their new plant at Samba in Jammu Kashmir to manufacture products for the domestic markets. Also, they set up a new state of the art Research Development center at Mohali, Punjab with an investment of USD 5 million. They increased the production capacity of bulk drugs/ intermediates by 87.03 TPA to 237.03 TPA.During the year, the company launched new products namely, Letrozole, Anastrozole (AntiCancer) Venlafaxine (AntiDepressants) Lavofloxacin (AntiBiotic) Quetipine Aripirazole (AntiPshychotic) in the market. They entered into a joint venture with Farayand Chemi Hakim Co, a private joint stock company registered under the law of Iran to focus on the marketing of the products in Middle East Iran. During the year 200607, the company expanded the production capacity of bulk drugs/ intermediates by 18.85 TPA to 255.88 TPA. In April 2006, the company inaugurated their new manufacturing facilities at Baddi in Himachal Pradesh to manufacture tablets, injectibles and liquids.During the year 200708, the company entered into the field of Phytochemicals, where, the company has put to operation a new manufacturing facility to manufacture mintbased products. They increased the production capacity of bulk drugs/ intermediates by 162.30 TPA to 418.18 TPA.During the year 2010, Company incorporated two new subsidiaries one in Dubai under the name of M/s IndSwift Middle East FZE,UAE and Second in Singapore under the name of M/s IndSwift Laboratories Pte Ltd., Singapore. The company launched new drugs likeDutasteride Cinacalcet, Duloxetine, Mecloxamine citrate, Atomoxetine, Exemestane, Ezetimibe, Pregabalin, Ranolazine, Telmisartan Posaconazole in 2010. It commercialized the production of Mecloxamine citrate, Bexarotene and Dutasteride, developed new processes for key intermediates of Sunitinib and Mitiglinide calcium and robust and reproducible process developed for polymorph FORM I of Rifaximin in year 2011. During the financial year 2013, the Company had transferred its investment in Iran Joint Venture to its Dubai Subsidiary, which already completed the process of disinvestment.During the year 201314, 16,92,725 equity shares were allotted on 3rd February, 2014 on preferential basis to promoters and promoter group company at a price of Rs.55/ per share (including premium of Rs.45/ per share) and consequent to the allotment the paid up share capital of the Company stand at Rs.40,96,31,950/ consisting 4,09,63,195/ equity shares of Rs.10/ each.During 201516, 3 new products Nateglinide, Ezitimibe and Rosuvastatin were launched commercially and Lisdexamphentamine, a new product was supplied in the biobatch quantities.During 201920, Mohali Green Environment Private Limited (MGEPL) ceased to be an Associate Company as Companys investment in MGEPL fell from 25.30% to 19.95%. as on 31st March, 2020.During 202021, Fortune (India) Constructions Limited (100%) and Halcyon Life Sciences Pvt. Ltd. (98.19%) became the wholly ownedsubsidiary of the company consequent to the Company acquiring/ subscribing to the total equity capital of these Companies. Fortune(India) Constructions Limited ceased to be the associate as it became the wholly owned subsidiary of the company.As on 31.03.2021, Company had 5 Subsidiaries i.e. IndSwift Laboratories Inc. (US Subsidiary), IndSwift Middle East FZLLC (Dubai Subsidiary), Meteoric Life Sciences PTE Ltd. (Singapore Subsidiary), Fortune (India) Constructions Limited (Indian Subsidiary) and Halcyon Life Sciences Pvt Ltd (Indian Subsidiary).During the Year 202122, M/s Meteoric Life Sciences Pte Ltd ceased to be a subsidiary of the Company with effect from August 10, 2021and M/s IndSwift Middle East FZE ceased to be subsidiary of the Company with effect from May 27, 2021 consequent to its sale to M/s. Soft Air General Trading LLC, UAE. The Company entered two Joint Ventures to enter into explore new avenues available in the pharma fields. One joint venture was with M/s Wellgen Medicare LLP a Delhi based pharma trading concern and Mr. Anshul Jain on a 50:50 partnership basis a LLP named Indis Healthcare LLP. The Company also entered into an another joint venture with Mr. Ramesh Mehta as the partner on a 75:25 partnership basis by incorporating a private Company named MJM Remedies Private Limited.In FY 2024, the Company sold its complete API business CRAMS business under a slumpsale deal to PI Industries, effective on March 18, 2024. Further, the Company has also incorporated ISLL Middle East L.L.CFZ, wholly owned subsidiary in Dubai on 17052024.

    As of 10 Jul, 2025, Ind-Swift Laboratories share price is ₹105.6. The stock opened at ₹116.7 and had closed at ₹116.7 the previous day. During today’s trading session, Ind-Swift Laboratories share price moved between ₹105.00 and ₹119.37, with an average price for the day of ₹112.19. Over the last 52 weeks, the stock has recorded a low of ₹68.72 and a high of ₹186.00. In terms of performance, Ind-Swift Laboratories share price has increased by 0.6% over the past six months and has declined by 21.5% over the last year.

    Read More
    Ind-Swift Laboratories SIP Return Calculator

    Over the past

    1 year
    3 years
    5 years
    Total Investment of ₹65,00,000
    Would have become ₹58,46,077 (-10.06%)
    Daily SIP of 25,000 would have become 58,46,077 in 1 year with a gain of -6,53,922 (-10.06%)
    View details of Market Depth

    Ind-Swift Laboratories Fundamental

    Market Cap (in crs)

    640.38

    Face Value

    10

    Turnover (in lacs)

    881.65

    Key Metrics

    Qtr Change %
    43.20% Fall from 52W High
    27.7
    Dividend yield 1yr %
    0

    Ind-Swift Laboratories Key Financials

    View more

    *All values are in ₹ Cr.

    *All values are in ₹ Cr.

    *All values are in ₹ Cr.

    *All values are in ₹ Cr.

    Ind-Swift Laboratories Quarterly Revenue
    Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    8.66 Cr
    11.96 Cr
    33.17 Cr
    393.33 Cr
    287.51 Cr
    Ind-Swift Laboratories Yearly Revenue
    Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020Mar 2019
    1326.27 Cr
    1240.81 Cr
    1081.45 Cr
    914.04 Cr
    813.04 Cr
    793.51 Cr
    Ind-Swift Laboratories Quarterly Net Profit/Loss
    Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    -0.01 Cr
    0.4 Cr
    1.01 Cr
    238.87 Cr
    19.53 Cr
    Ind-Swift Laboratories Yearly Net Profit/Loss
    Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020Mar 2019
    421.45 Cr
    47.83 Cr
    -2.15 Cr
    -3.15 Cr
    -21.19 Cr
    28.95 Cr

    Ind-Swift Laboratories Result Highlights

    • Ind-Swift Laboratories Ltd reported a 9.9% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Dec (Q3FY25). On a year-on-year (YoY) basis, it witnessed a decline of 92.4%.

    • Its expenses for the quarter were down by 3.4% QoQ and 91.3% YoY.

    • The net profit decreased 97.6% QoQ and decreased 99.9% YoY.

    • The earnings per share (EPS) of Ind-Swift Laboratories Ltd - at - during Q3FY25.

      Read more

    Data Source: BSE, Company announcements

    The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results.

    Top Mutual Fund Invested in Ind-Swift Laboratories

    Promoter
    40.9%
    Foreign Institutions
    3.1%
    Domestic Institutions
    0.9%
    Public
    55.1%
    Promoter
    42%
    Foreign Institutions
    0.5%
    Domestic Institutions
    0.9%
    Public
    56.6%
    Promoter
    42%
    Foreign Institutions
    0.6%
    Domestic Institutions
    1%
    Public
    56.4%
    Promoter
    42%
    Foreign Institutions
    1.3%
    Domestic Institutions
    0.9%
    Public
    55.8%
    Promoter
    42%
    Foreign Institutions
    0.3%
    Domestic Institutions
    8%
    Public
    49.7%
    Promoter
    42%
    Foreign Institutions
    0.3%
    Domestic Institutions
    18.7%
    Public
    39%

    Ind-Swift Laboratories Technical Analysis

    Moving Averages Analysis
    105.23
    Current Price
    Bullish Moving Averages
    8
    Bearish Moving Averages
    8
    5Day EMA
    112.80
    10Day EMA
    112.60
    12Day EMA
    112.00
    20Day EMA
    108.80
    26Day EMA
    106.30
    50Day EMA
    99.60
    100Day EMA
    96.80
    200Day EMA
    100.30
    5Day SMA
    115.00
    10Day SMA
    113.50
    20Day SMA
    109.90
    30Day SMA
    104.80
    50Day SMA
    92.60
    100Day SMA
    90.40
    150Day SMA
    96.20
    200Day SMA
    100.90
    Delivery & Volume

    Delivery & Volume

    PeriodCombined Delivery VolumeNSE+BSE Traded Volume
    Day Rs
    505470 Rs
    914006 Rs
    Week Rs
    268476 Rs
    513647 Rs
    Month Rs
    227430 Rs
    499325 Rs
    110.00
    Pivot
    Resistance
    First Resistance
    115.01
    Second Resistance
    124.37
    Third Resistance
    129.38
    Support
    First Support
    100.64
    Second support
    95.63
    Third Support
    86.27
    Relative Strength Index
    49.62
    Money Flow Index
    68.07
    MACD
    5.68
    MACD Signal
    6.58
    Average True Range
    6.47
    Average Directional Index
    48.76
    Rate of Change (21)
    -4.20
    Rate of Change (125)
    -1.11
    Name
    Holding Percent
    ZEAL GLOBAL OPPORTUNITIES FUND
    2.53

    Ind-Swift Laboratories Latest News

    04 JUL 2025 | Friday

    Ind-Swift Laboratories Ltd - 532305 - Intimation Regarding Re-Constitution Of Various Committees Of The Board Of The Company

    04 JUL 2025 | Friday

    Ind-Swift Laboratories Ltd - 532305 - Announcement under Regulation 30 (LODR)-Change in Management

    04 JUL 2025 | Friday

    Ind-Swift Laboratories Ltd - 532305 - Disclosure Under Regulation 7(2) Read With Regulation 6(2) Of The SEBI (Prohibition Of Insider Trading) Regulations, 2015

    View More

    Ind-Swift Laboratories Share Price FAQs

    Ind-Swift Laboratories share price is ₹105.23 in NSE and ₹105.95 in BSE as on 10/7/2025.

    Ind-Swift Laboratories share price in the past 1-year return was -21.5. The Ind-Swift Laboratories share hit a 1-year low of Rs. 68.72 and a 1-year high of Rs. 186.

    The market cap of Ind-Swift Laboratories is Rs. 640.38 Cr. as of 10/7/2025.

    The PE ratios of Ind-Swift Laboratories is 7.14 as of 10/7/2025.

    The PB ratios of Ind-Swift Laboratories is 0.62 as of 10/7/2025

    You can easily buy Ind-Swift Laboratories shares in Kotak Securities by opening a demat account and getting the KYC documents verified online.

    The 52-week high and low of Ind-Swift Laboratories share price is ₹186 and ₹68.72 as of 10/7/2025.

    Please be aware that Ind-Swift Laboratories stock prices are subject to continuous fluctuations due to various factors.

    Popular Stocks
    65.97
    +0.03 (+0.05%)
    137.13
    -0.46 (-0.33%)
    695.60
    +2.80 (+0.40%)
    2,581.00
    -2.00 (-0.08%)
    169.64
    +3.73 (+2.25%)
    384.70
    -0.40 (-0.10%)
    160.66
    +1.66 (+1.04%)
    262.85
    -1.70 (-0.64%)
    413.50
    -4.15 (-0.99%)
    399.90
    -0.75 (-0.19%)
    Top Gainers
    12,650.00
    +180.00 (+1.44%)
    852.85
    +12.10 (+1.44%)
    160.66
    +1.66 (+1.04%)
    947.65
    +7.05 (+0.75%)
    2,039.40
    +13.00 (+0.64%)
    Top Losers
    1,964.50
    -55.20 (-2.73%)
    771.25
    -15.05 (-1.91%)
    2,451.20
    -47.70 (-1.91%)
    7,359.00
    -110.00 (-1.47%)
    671.75
    -9.30 (-1.37%)
    Open Demat Account
    +91 -

    Open Demat Account
    +91 -